Long-term data on rituximab in DLBCL Oncology Update Rituximab's efficacy with CHOP in diffuse large-B-cell lymphoma at six years has been demonstrated in a study published in the Lancet this week. The follow-up of the MInT trial was “reassuring”, according to an accompanying editorial, which noted it ... |
